Compare Citius Pharmaceuticals Inc (CTXR) vs Gold Fields Limited (GFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Gold Fields Limited — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Gold Fields Limited trades at $36.82 (market cap $31.87B). The key difference: Gold Fields Limited is far larger — about 2339.9× Citius Pharmaceuticals Inc's market cap, and Gold Fields Limited pays a 6% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Gold Fields Limited for 49 Days on average.
| CTXR | GFI | |
|---|---|---|
Market Cap | $13.62M | $31.87B |
Volume | 132,438 | 4,169,651 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $61.52 |
52-Week Low | $0.48 | $31.25 |
Typical Hold Time | 17 Days | 49 Days |
Enterprise Value | $3.79M | $32.47B |
Dividend Yield | — | 6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
Gold Fields (GFI) trades at $35.86, up 2.31% today, amid a bearish technical signal and mixed earnings history. The stock shows strong fundamentals with a P/E of 7.3, net income margin of 38.66%, and robust cash flow growth, while recent news highlights a rejected $27 billion takeover bid for Northern Star, creating investor uncertainty.
The outlook is balanced: valuation metrics and profitability support upside toward the $52.75 analyst target, but near-term risks include acquisition-related volatility and technical weakness. Investors should weigh high ROE and cash returns against execution risks from expansion efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
